gemapharm limited Company Information
Company Number
03597444
Next Accounts
Mar 2026
Industry
Wholesale of pharmaceutical goods
Shareholders
saville holdings ltd
a-f sarl
Group Structure
View All
Contact
Registered Address
10 saville court saville place, clifton, bristol, BS8 4EJ
Website
gemapharm.comgemapharm limited Estimated Valuation
Pomanda estimates the enterprise value of GEMAPHARM LIMITED at £4.7m based on a Turnover of £9.3m and 0.5x industry multiple (adjusted for size and gross margin).
gemapharm limited Estimated Valuation
Pomanda estimates the enterprise value of GEMAPHARM LIMITED at £4m based on an EBITDA of £821.6k and a 4.87x industry multiple (adjusted for size and gross margin).
gemapharm limited Estimated Valuation
Pomanda estimates the enterprise value of GEMAPHARM LIMITED at £4.9m based on Net Assets of £2.5m and 1.97x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Gemapharm Limited Overview
Gemapharm Limited is a live company located in bristol, BS8 4EJ with a Companies House number of 03597444. It operates in the wholesale of pharmaceutical goods sector, SIC Code 46460. Founded in July 1998, it's largest shareholder is saville holdings ltd with a 90% stake. Gemapharm Limited is a mature, mid sized company, Pomanda has estimated its turnover at £9.3m with high growth in recent years.
Upgrade for unlimited company reports & a free credit check
Gemapharm Limited Health Check
Pomanda's financial health check has awarded Gemapharm Limited a 5 rating. We use a traffic light system to show it exceeds the industry average on 5 measures and has 2 areas for improvement. Company Health Check FAQs
5 Strong
4 Regular
2 Weak
Size
annual sales of £9.3m, make it smaller than the average company (£25m)
- Gemapharm Limited
£25m - Industry AVG
Growth
3 year (CAGR) sales growth of 25%, show it is growing at a faster rate (5.6%)
- Gemapharm Limited
5.6% - Industry AVG
Production
with a gross margin of 28.5%, this company has a comparable cost of product (28.5%)
- Gemapharm Limited
28.5% - Industry AVG
Profitability
an operating margin of 8.9% make it more profitable than the average company (4.2%)
- Gemapharm Limited
4.2% - Industry AVG
Employees
with 2 employees, this is below the industry average (36)
2 - Gemapharm Limited
36 - Industry AVG
Pay Structure
on an average salary of £80.6k, the company has an equivalent pay structure (£80.6k)
- Gemapharm Limited
£80.6k - Industry AVG
Efficiency
resulting in sales per employee of £4.6m, this is more efficient (£662.4k)
- Gemapharm Limited
£662.4k - Industry AVG
Debtor Days
it gets paid by customers after 69 days, this is near the average (58 days)
- Gemapharm Limited
58 days - Industry AVG
Creditor Days
its suppliers are paid after 84 days, this is slower than average (27 days)
- Gemapharm Limited
27 days - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- Gemapharm Limited
- - Industry AVG
Cash Balance
has cash to cover current liabilities for 44 weeks, this is more cash available to meet short term requirements (13 weeks)
44 weeks - Gemapharm Limited
13 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 54.1%, this is a similar level of debt than the average (50.3%)
54.1% - Gemapharm Limited
50.3% - Industry AVG
GEMAPHARM LIMITED financials
Gemapharm Limited's latest turnover from June 2024 is estimated at £9.3 million and the company has net assets of £2.5 million. According to their latest financial statements, Gemapharm Limited has 2 employees and maintains cash reserves of £1.9 million as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 | Jun 2016 | Jun 2015 | Jun 2014 | Jun 2013 | Jun 2012 | Jun 2011 | Jun 2010 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Turnover | 7,782,737 | 4,775,067 | |||||||||||||
Other Income Or Grants | 0 | 0 | |||||||||||||
Cost Of Sales | 5,549,475 | 3,630,982 | |||||||||||||
Gross Profit | 2,233,262 | 1,144,085 | |||||||||||||
Admin Expenses | 1,950,029 | 970,000 | |||||||||||||
Operating Profit | 283,233 | 174,085 | |||||||||||||
Interest Payable | 0 | 0 | |||||||||||||
Interest Receivable | 0 | 0 | |||||||||||||
Pre-Tax Profit | 283,233 | 174,085 | |||||||||||||
Tax | -45,463 | -35,315 | |||||||||||||
Profit After Tax | 237,770 | 138,770 | |||||||||||||
Dividends Paid | 0 | 0 | |||||||||||||
Retained Profit | 237,770 | 138,770 | |||||||||||||
Employee Costs | |||||||||||||||
Number Of Employees | 2 | 2 | 3 | 3 | 3 | 3 | 1 | ||||||||
EBITDA* | 283,233 | 174,085 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 | Jun 2016 | Jun 2015 | Jun 2014 | Jun 2013 | Jun 2012 | Jun 2011 | Jun 2010 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Tangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments & Other | 7,633 | 7,633 | 8,219 | 8,219 | 7,695 | 7,981 | 8,142 | 8,142 | 8,082 | 0 | 0 | 0 | 0 | 0 | 0 |
Debtors (Due After 1 year) | 1,681,187 | 752,371 | 0 | 0 | 209,937 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Total Fixed Assets | 1,688,820 | 760,004 | 8,219 | 8,219 | 217,632 | 7,981 | 8,142 | 8,142 | 8,082 | 0 | 0 | 0 | 0 | 0 | 0 |
Stock & work in progress | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Trade Debtors | 1,761,112 | 1,528,701 | 3,400,566 | 1,530,166 | 280,233 | 290,690 | 248,480 | 0 | 24,912 | 24,477 | 16,168 | 42,932 | 44,556 | 51,698 | 53,274 |
Group Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Misc Debtors | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 55,511 | 4,425 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash | 1,929,331 | 1,848,026 | 2,521,303 | 2,132,927 | 1,478,504 | 299,147 | 658,276 | 736,478 | 98,698 | 31,196 | 30,296 | 0 | 0 | 0 | 0 |
misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
total current assets | 3,690,443 | 3,376,726 | 5,921,869 | 3,663,094 | 1,758,737 | 589,837 | 906,756 | 791,990 | 128,036 | 55,674 | 46,463 | 42,932 | 44,556 | 51,698 | 53,274 |
total assets | 5,379,262 | 4,136,731 | 5,930,088 | 3,671,313 | 1,976,369 | 597,818 | 914,897 | 800,131 | 136,117 | 55,674 | 46,463 | 42,932 | 44,556 | 51,698 | 53,274 |
Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Trade Creditors | 1,530,600 | 660,629 | 2,390,977 | 795,767 | 584,890 | 218,014 | 195,611 | 0 | 0 | 1,066 | 4,316 | 0 | 0 | 0 | 0 |
Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
other current liabilities | 733,376 | 869,687 | 763,910 | 502,676 | 444,334 | 223,072 | 597,148 | 699,731 | 86,216 | 0 | 0 | 0 | 0 | 0 | 0 |
total current liabilities | 2,263,976 | 1,530,316 | 3,154,887 | 1,298,443 | 1,029,224 | 441,087 | 792,760 | 699,731 | 86,216 | 1,066 | 4,316 | 0 | 0 | 0 | 0 |
loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
other liabilities | 648,438 | 813,646 | 876,178 | 711,617 | 692,115 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
total long term liabilities | 648,439 | 813,646 | 876,179 | 711,617 | 692,116 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
total liabilities | 2,912,415 | 2,343,962 | 4,031,066 | 2,010,060 | 1,721,340 | 441,087 | 792,760 | 699,731 | 86,216 | 1,066 | 4,316 | 0 | 0 | 0 | 0 |
net assets | 2,466,848 | 1,792,768 | 1,899,022 | 1,661,252 | 255,029 | 156,731 | 122,138 | 100,400 | 49,901 | 54,608 | 42,147 | 42,932 | 44,556 | 51,698 | 53,274 |
total shareholders funds | 2,466,848 | 1,792,768 | 1,899,022 | 1,661,252 | 255,029 | 156,731 | 122,138 | 100,400 | 49,901 | 54,608 | 42,147 | 42,932 | 44,556 | 51,698 | 53,274 |
Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 | Jun 2016 | Jun 2015 | Jun 2014 | Jun 2013 | Jun 2012 | Jun 2011 | Jun 2010 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Activities | |||||||||||||||
Operating Profit | 283,233 | 174,085 | |||||||||||||
Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Tax | -45,463 | -35,315 | |||||||||||||
Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Debtors | 1,161,227 | -1,119,494 | 1,870,399 | 1,039,996 | 199,480 | 42,210 | 192,969 | 26,174 | 4,860 | 8,310 | -26,765 | -1,623 | -7,143 | -1,576 | 53,274 |
Creditors | 869,971 | -1,730,348 | 1,595,210 | 210,877 | 366,876 | 22,403 | 195,611 | 0 | -1,066 | -3,251 | 4,316 | 0 | 0 | 0 | 0 |
Accruals and Deferred Income | -136,311 | 105,777 | 261,234 | 58,342 | 221,262 | -374,076 | -102,583 | 613,515 | 86,216 | 0 | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes & Provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Cash flow from operations | 223,815 | -632,007 | |||||||||||||
Investing Activities | |||||||||||||||
capital expenditure | |||||||||||||||
Change in Investments | -1 | -586 | 0 | 524 | -287 | -160 | 0 | 60 | 8,082 | 0 | 0 | 0 | 0 | 0 | 0 |
cash flow from investments | |||||||||||||||
Financing Activities | |||||||||||||||
Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
other long term liabilities | -165,208 | -62,532 | 164,561 | 19,502 | 692,115 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
share issue | |||||||||||||||
interest | 0 | 0 | |||||||||||||
cash flow from financing | 164,561 | 1,286,956 | |||||||||||||
cash and cash equivalents | |||||||||||||||
cash | 81,305 | -673,277 | 388,376 | 654,424 | 1,179,357 | -359,129 | -78,202 | 637,780 | 67,501 | 901 | 30,296 | 0 | 0 | 0 | 0 |
overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
change in cash | 81,305 | -673,277 | 388,376 | 654,424 | 1,179,357 | -359,129 | -78,202 | 637,780 | 67,501 | 901 | 30,296 | 0 | 0 | 0 | 0 |
gemapharm limited Credit Report and Business Information
Gemapharm Limited Competitor Analysis
Perform a competitor analysis for gemapharm limited by selecting its closest rivals, whether from the WHOLESALE AND RETAIL TRADE; REPAIR OF MOTOR VEHICLES AND MOTORCYCLES sector, other mid companies, companies in BS8 area or any other competitors across 12 key performance metrics.
gemapharm limited Ownership
GEMAPHARM LIMITED group structure
Gemapharm Limited has no subsidiary companies.
gemapharm limited directors
Gemapharm Limited currently has 4 directors. The longest serving directors include Mr Andrew Lamb (Dec 2013) and Mr Bernard Schack (Apr 2015).
officer | country | age | start | end | role |
---|---|---|---|---|---|
Mr Andrew Lamb | 74 years | Dec 2013 | - | Director | |
Mr Bernard Schack | Portugal | 79 years | Apr 2015 | - | Director |
Mr Hussain Al-Tahan | United Kingdom | 32 years | Nov 2020 | - | Director |
Mr Romain Arnal | United Kingdom | 46 years | Apr 2024 | - | Director |
P&L
June 2024turnover
9.3m
+47%
operating profit
821.6k
0%
gross margin
28.5%
+6.17%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
June 2024net assets
2.5m
+0.38%
total assets
5.4m
+0.3%
cash
1.9m
+0.04%
net assets
Total assets minus all liabilities
gemapharm limited company details
company number
03597444
Type
Private limited with Share Capital
industry
46460 - Wholesale of pharmaceutical goods
incorporation date
July 1998
age
27
incorporated
UK
ultimate parent company
accounts
Total Exemption Full
last accounts submitted
June 2024
previous names
kenworld limited (April 2000)
seaway pharma limited (February 2000)
accountant
COLLINS JOHNSON CORPORATE SERVICES LTD
auditor
-
address
10 saville court saville place, clifton, bristol, BS8 4EJ
Bank
-
Legal Advisor
-
gemapharm limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to gemapharm limited.
gemapharm limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for GEMAPHARM LIMITED. This can take several minutes, an email will notify you when this has completed.
gemapharm limited Companies House Filings - See Documents
date | description | view/download |
---|